Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy
Breast cancer survivors receiving endocrine (hormonal) therapy (aromatase inhibitors) are at high risk for cancer treatment-induced bone loss and osteoporosis due to estrogen depletion.
• Female breast cancer survivors aged 40-60 years.
• Histologically confirmed stage I-III breast cancer.
• Currently receiving hormonal therapy (aromatase inhibitors) for at least 3 months.
• At risk of osteoporosis or with low bone mineral density (BMD) defined by T-score ≤ -1.0 at lumbar spine or hip.
• Medically cleared for exercise, specifically low-to-moderate intensity Pilates.
• Able to attend supervised exercise sessions three times per week for 12 weeks.
• Willing and able to provide written informed consent.